Navigation Links
Pennsaid(R) Phase 3 study results to be published in leading international PAIN journal
Date:4/23/2009

request to review the side effect profile of Pennsaid if combined with an oral NSAID. This combination showed no increased incidence of the usual systemic side effects, just the expected additive profiles of Pennsaid alone plus oral diclofenac alone.

Dry skin was the most common adverse event with Pennsaid use. Fewer digestive system adverse events and laboratory abnormalities (decreased hemoglobin and increased AST, ALT and creatinine) were observed with Pennsaid as compared to oral diclofenac.

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid(R), a topical non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development Center in San Diego California. For more information, please visit.www.nuvoresearch.com

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are
'/>"/>

SOURCE Nuvo Research Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nuvo Research Announces Successful Completion Of All Pennsaid(R) Studies
2. FDA Accepts Nuvos Resubmission For Pennsaid(R)
3. Ovation further advances development pipeline with new phase III epilepsy study
4. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
5. Mannatech Launches Phase One of New Sales and Training Tools
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Manic phase of bipolar disorder benefits from breast cancer medication
8. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
9. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
10. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
11. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... , ... On May 29, 2015, Health Canada announced that they had registered ... for gluten free oats and foods that contain them as ingredients. , “We are ... to include gluten-free oat products in Canada,” says Frank Massong, VP of Regulatory and ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... announced they have been selected by the Department of Vermont Health Access to ... Medicaid Management Information System (MMIS) and Integrated Contact Center System project. , Vermont ...
(Date:7/6/2015)... ... July 06, 2015 , ... Human ... drug discovery. iPSCs are generated from adult cells, such as blood or skin, ... in the human body. , iPSC-derived cardiomyocytes have proven valuable ...
(Date:7/6/2015)... ... July 06, 2015 , ... University of Pittsburgh Cancer Institute ... thyroid cancer testing to reflect newly available tests that better incorporate personalized medicine into ... to interpret thyroid cancer tests is published in the July issue of the scientific ...
(Date:7/6/2015)... Branford, Connecticut (PRWEB) , ... July 06, 2015 ... ... Aesthetic Medical Practice & Medical Spa industries, announces the return of its complimentary ... the Acara team of aesthetic medical business leaders creates success for their clients ...
Breaking Medicine News(10 mins):Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3
... study has indicated that the culprit to most health threat ... used for cooking and heating. According to the UN 5% ... indoor air pollution. ,This study is based on ... air pollution is the physical, chemical, and biological characteristics of ...
... major new cancer research study that may be the last ... United States to discover the genetic and environmental factors that ... 3 (CPS-3) aims to enroll a geographically and ethnically diverse ... to help pave the way for the next generation of ...
... Eye Institute is seeking to raise glaucoma awareness among Mexican-Americans, ... others, the Casa Grande Valley Dispatch reports. ... with a family history of glaucoma all face a higher ... open-angle glaucoma, the most common form glaucoma. ...
... American Journal of Gastroenterology suggests that smoking may determine ... those who suffer from Crohns disease. Where the ... eventually require surgical treatment. ,In patients who ... the small intestine, rather than the colon, says study ...
... protein called tau helped in the reduction of Alzheimers symptoms ... helping find treatment to a deadly brain disorder, scientists ... California, San Francisco said, If this strategy also works in ... ability" ,The researchers, whose work is published in ...
... substantial advancements and success have led to the current imbalance ... them. The United Network for Organ Sharing (UNOS) coordinates the ... wait time, sensitization and HLA matching. ,When ... at the top of the national list. A recent editorial ...
Cached Medicine News:Health News:American Cancer Society Launches Major New Study 2Health News:American Cancer Society Launches Major New Study 3Health News:Who Receives a Kidney Transplant First? 2
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July ... ), a leading global pharmaceutical company, and Oculeve, a ... for dry eye disease, today announced that they have ... Oculeve in an all-cash transaction.  Under the terms of ... million upfront payment and commercialization milestone payments related to ...
(Date:7/6/2015)... -- China Information Technology, Inc. (the "Company" or "CNIT") ... platform, exchange, and big data solutions in ... its mobile app for Healthcare One Pass, ushering in ... devices. The Company jointly hosted the launch ceremony with ... Shenzhen News Net.   The mobile app for ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... ... Anticancer Drug, HOUSTON, ... to families, workplaces and communities, and many,Houstonians are aware of ... the CHRISTUS Stehlin Foundation for,Cancer Research, a nationally recognized leader ...
Journalists and other readers should disregard the news release "Oramed,Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository",OTC:ORMP, issued earlier today. The release was transmitted...
Cached Medicine Technology:Local Research Foundation Achieves Milestone in Fight Against Cancer 2Local Research Foundation Achieves Milestone in Fight Against Cancer 3
... Split Splint reduces PIP joint or DIP joint ... to put on. Soft gel-lining cushions injured fingers ... begin earlier for faster, more successful therapy results. ... and at night to maintain gains in motion. ...
... FoamWrap Final Flexion Wraps restore full PIP ... or when lost due to arthritic changes. ... foam-lined material hugs the finger to prevent ... restore motion. One size. Sold in packages ...
One splint does it all....
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
Medicine Products: